

United Against Cancer Ljubljana, 4 November 2006




Differences in the outcome of cancer care across Europe






New cases and deaths per 100,000 per year around 2000, Europe vs N America: women





Iceland * Finland * Norway * **EUROCARE-3 (2003)** Sweden * **Denmark*** England 22 countries Scotland * Wales * 42 types of adult cancer Austria France • 24 childhood malignancies Germany Italy • 67 cancer registries Malta * • 1.8 million adults 1990-94 **Netherlands** Portugal • Follow-up to 1999 Spain Switzerland **Czech Republic** Estonia * Poland Slovakia * * national cancer data Slovenia*





EUROCARE-3 – survival up to 1999 population base and numbers of patients


Countries	Population (thousands)	Patients included
EU states (11)	343,278	1,554,296
EU in 2004 (6)	58,026	166,249
Other states (3)	11,799	95,039
TOTAL (22)	413,103	1,815,584

















Prostate cancer survival trends to 1999 Europe, men diagnosed 1983-94







European variation in cancer survival what can be inferred?

- Wide differences for many cancers (not all)
- Stage at diagnosis is a key factor: education
- Increasing gap between East and West
- Evidence is adequate for health policy

Need for:

- Investment in prevention and health systems
- Wider, co-ordinated surveillance EU role?
- Constant methodological development
- Legislate and invest to support registry function

Europe-wide *surveillance* of cancer survival – EUROCARE-4 (2007)

- Timely, high-quality, population-based
- Europe-wide
- Trend analyses
- Incidence, mortality and survival
- Prevalence by time since diagnosis
- Inclusion of stage and pathology data
- Timely surveillance of patterns of care
- Period analysis for short-term predictions